A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
Vivos Inc. Monthly Reports
At Vivos Inc. we are committed to updating the public with our monthly and quarterly reports.
We are proud to be at the forefront of innovative cancer treatments with our patented Precision Radionuclide Therapy™ and it is our mission to one day have our technology save lives worldwide.
December 2024 Monthly Report
November 2024 Monthly Report
October 2024 Monthly Update
August 2024 Monthly Report
July 2024 Monthly Report
May 2024 Monthly Report
Vivos Inc. is dedicated to IDE Submission
Vivos Inc. was busy within our RadioGel® division, reviewing the documents necessary to submit the IDE before the end of June and refining our manufacturing and quality management documents. May 1 launched our new RadioGel® website with 6x our normal views. Our IsoPet® division created new marketing materials in preparation for veterinary conferences in June and July. Expanding the IsoPet® Regional Clinic base is the goal for 2024.
Our IsoPet® division is expanding!
Our IsoPet® division is expanding across the USA and looking for veterinary clinics to become a Certified Regional IsoPet® Clinic. For more information on how your clinic offer a safer, more effective cancer treatment in your practice please visit our IsoPet® website
April 2024 Monthly Report
It's been a busy month at Vivos Inc.
At Vivos Inc. we are committed to helping cancer patients (currently just furry patients with our IsoPet® division) with our life changing technology. Our team of scientists and researchers are dedicated to reaching the finish line with our IDE Submission for FDA approval to move forward with RadioGel®. We are proud to be at the forefront with our patented Precision Radionuclide Therapy™ and it is our mission to one day have our technology save lives worldwide.
What is Precision Radionuclide Therapy™ and RadioGel®?
Our patented Precision Radionuclide Therapy™ (PRnT™) is the future of cancer treatment – the insertion of our radionuclide device directly into the tumor tissue. Our RadioGel® division for human cancers is in the final stages of preparing to submit the necessary documents for IDE Submission for approval to begin human trials at the Mayo Clinic.